METABOLIC SYNDROME INPATIENTS WITH RHEUMATOID ARTHRITIS

Document Type : Original Article

Authors

1 Department of Rheumatology, Rehabilitation and Physical medicine - Faculty of Medicine- Sohag University.

2 Department of Internal Medicine- Faculty of Medicine- Sohag University

Abstract

Objectives:To determine the prevalence of metabolic syndrome (MetS) in patients with rheumatoid arthritis (RA) and to evaluate the relation between parameters of MetS and clinical aspects of RA.
Design: Cross-sectional study.
Patients:Patients with rheumatoid arthritis (RA) according to 2010 ACR/EULAR classification criteria for RA (n = 150).
Methods: Demographic data, arthritis history, medical and therapeutic history were evaluated. Height, weight, BMI, waist circumference (WC) and blood pressure (BP) were recorded. Disease activity was evaluated using DAS28 (ESR). Immunological investigations included RF, ESR, CRP, and anti-CCP. Fasting blood glucose and lipid profile were measured.The patient was diagnosed as having MetS according to 3 definitions; ATPIII (2004), IDF (2005), and JIS (2009).
Results:Prevalence of MetS in rheumatoid patients was 48% (ATPIII definition), 52 % (IDF definition), and 46 % (JIS definition with Egyptian cut-off of WC), respectively. The most prevalent component of MetS was central obesity (75.3- 92 % according to the used definition).DAS28 was significantly higher in patients with MetS with higher number of tender joints and VAS (0-100) and most rheumatoid patients with MetS (68 %) had high disease activity.
Conclusions:The increased prevalence of MetS components in RA patients, suggests greater attention be given to modifiable risk factors, including improvement of dietary habits, physical activity and blood pressure control.

Keywords


REFERENCES
1. Smolen JS, Aletaha D and Mcinnes IB: Rheumatoid arthritis.Lancet. 2016; 388(10055): 2023-2038.
2. Silman AJ and Pearson JE: Epidemiology and genetics of rheumatoid arthritis.Arthritis Res. 2002; 4 Suppl 3: S265-72.
3. Kramer HR and Giles JT: Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity.Arthritis Care Res (Hoboken). 2011; 63(4): 484-99.
4. Lopez-Mejias R, Castaneda S, Gonzalez-Juanatey C, Corrales A, Ferraz-Amaro I: Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers.Autoimmun Rev. 2016; 15(11): 1013-1030.
5. Rochlani Y, Pothineni NV, Kovelamudi S and Mehta JL: Metabolic syndrome: pathophysiology, management, and modulation by natural compounds.Ther Adv Cardiovasc Dis. 2017: 1753944717711379.
 
6. Tune JD, Goodwill AG, Sassoon DJ and Mather KJ: Cardiovascular consequences of metabolic syndrome.Transl Res. 2017; 183: 57-70.
7. Zhang J, Fu L, Shi J, Chen X, Li Y: The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies.PLoS One. 2013; 8(10): e78151.
8. Parra-Salcedo F, Contreras-Yanez I, Elias-Lopez D, Aguilar-Salinas CA and Pascual-Ramos V: Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity.Arthritis Res Ther. 2015; 17: 34.
9. Kerekes G, Nurmohamed MT, Gonzalez-Gay MA, Seres I, Paragh G: Rheumatoid arthritis and metabolic syndrome.Nat Rev Rheumatol. 2014; 10(11): 691-6.
10. Lee SG, Kim JM, Lee SH, Kim KH, Kim JH: Is the frequency of metabolic syndrome higher in South Korean women with rheumatoid arthritis than in healthy subjects? Korean J Intern Med. 2013; 28(2): 206-15.
11. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK: Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study.Ann Rheum Dis. 2007; 66(1): 28-33.
12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Ann Rheum Dis. 2010; 69(9): 1580-8.
13. Jung YO and Kim HA: Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis.Korean J Intern Med. 2012; 27(4): 378-87.
14. Grundy SM, Brewer HB, Cleeman JI, Smith SC and Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.Circulation. 2004; 109(3): 433-8.
15. Alberti KG, Zimmet P and Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.Diabet Med. 2006; 23(5): 469-80.
16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.Circulation. 2009; 120(16): 1640-5.
17. Assaad-Khalil SH, Mikhail MM, Aati TA, Zaki A, Helmy MA: Optimal waist circumference cutoff points for the determination of abdominal obesity and detection of cardiovascular risk factors among adult Egyptian population.Indian J Endocrinol Metab. 2015; 19(6): 804-10.
18. De Oliveira BM, Medeiros MM, De Cerqueira JV, De Souza Quixada RT and De Oliveira IM: Metabolic syndrome in patients with rheumatoid arthritis followed at a University Hospital in Northeastern Brazil.Rev Bras Reumatol Engl Ed. 2016; 56(2): 117-25.
19. Gomes KWP, Luz AJP, Felipe MRB, Beltrao LA, Sampaio AXC: Prevalence of metabolic syndrome in rheumatoid arthritis patients from Northeastern Brazil: Association with disease activity.Mod Rheumatol. 2017: 1-6.
20. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA: Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis.Diab Vasc Dis Res. 2007; 4(2): 130-5.
21. Toms TE, Panoulas VF, John H, Douglas KM and Kitas GD: Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.Arthritis Res Ther. 2009; 11(4): R110
22. Santos MJ, Vinagre F, Silva JJ, Gil V and Fonseca JE: Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of female patients.Acta Reumatol Port. 2010; 35(3): 325-32.
23. Dao HH, Do QT and Sakamoto J: Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study.Arthritis Res Ther. 2010; 12(6): R218.
24. Baker JF, Mehta NN, Baker DG, Toedter G, Shults J: Vitamin D, metabolic dyslipidemia, and metabolic syndrome in rheumatoid arthritis.Am J Med. 2012; 125(10): 1036 e9-1036 e15.
25. Karakoc M, Batmaz I, Sariyildiz MA, Tahtasiz M, Cevik R: The relationship of metabolic syndrome with disease activity and the functional status in patients with rheumatoid arthritis.J Clin Med Res. 2012; 4(4): 279-85.
26. Ormseth MJ, Lipson A, Alexopoulos N, Hartlage GR, Oeser AM: Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis.Arthritis Care Res (Hoboken). 2013; 65(9): 1410-5.
27. Salinas MJ, Bertoli AM, Lema L, Saucedo C, Rosa J: Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina.J Clin Rheumatol. 2013; 19(8): 439-43.
28. Rostom S, Mengat M, Lahlou R, Hari A, Bahiri R: Metabolic syndrome in rheumatoid arthritis: case control study.BMC Musculoskelet Disord. 2013; 14: 147.
29. Zafar ZA, Mahmud TH, Rasheed A and Wagan AA: Frequency of metabolic syndrome in Pakistani cohort of patients with rheumatoid arthritis.J Pak Med Assoc. 2016; 66(6): 671-6.
30. Pandey PK, Swami A, Biswas TK and Thakuria R: Prevalence of metabolic syndrome in treatment naive rheumatoid arthritis and correlation with disease parameters.Arch Rheumatol. 2017; 32(1): 46-52.
31. Goshayeshi L, Saber H, Sahebari M, Rezaieyazdi Z, Rafatpanah H: Association between metabolic syndrome, BMI, and serum vitamin D concentrations in rheumatoid arthritis.Clin Rheumatol. 2012; 31(8): 1197-203.
32. Da Cunha VR, Brenol CV, Brenol JC, Fuchs SC, Arlindo EM: Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity.Scand J Rheumatol. 2012; 41(3): 186-91.
33. Sahebari M, Goshayeshi L, Mirfeizi Z, Rezaieyazdi Z, Hatef MR: Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis.Scientific World J. 2011; 11: 1195-205.
34. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T: Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis.Atherosclerosis. 2008; 196(2): 756-63.
35. Abourazzak FE, Mansouri S, Najdi A, Tahiri L, Nejjari C: Prevalence of metabolic syndrome in patients with rheumatoid arthritis in Morocco: a cross-sectional study of 179 cases.Clin Rheumatol. 2014; 33(11): 1549-55.
36. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P: Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.Rheumatology (Oxford). 2007; 46(9): 1477-82.
37. Bajraktari IH, Rexhepi S, Berisha I, Lahu A, Kryeziu A: Prevalence of Asymptomatic Arterial Hypertension and Its Correlation with Inflammatory Activity in Early Rheumatoid Arthritis.Open Access Maced J Med Sci. 2017; 5(5): 641-644.
38. Erum U, Ahsan T and Khowaja D: Lipid abnormalities in patients with Rheumatoid Arthritis.Pak J Med Sci. 2017; 33(1): 227-230.
39. Galarza-Delgado DA, Azpiri-Lopez JR, Colunga-Pedraza IJ, Cardenas-De La Garza JA, Vera-Pineda R: Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis.Rheumatol Int. 2017.
40. Van Breukelen-Van Der Stoep DF, Van Zeben D, Klop B, Van De Geijn GJ, Janssen HJ: Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis.Rheumatology (Oxford). 2016; 55(7): 1210-6.
41. Ruscitti P, Ursini F, Cipriani P, Liakouli V, Carubbi F: Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study.PLoS One. 2017; 12(7): e0181203.